MyC Lands €10M to Revolutionize Employee Health Management in High-Risk Industries
By TechGuru • 2026-02-03T18:00:27.063684
In a significant development for the healthtech sector, MyC, a French software platform, has secured €10 million in funding to transform the way employee health is managed in complex, high-risk environments. The investment, led by Hi Inov and including IXO and existing investors Elaia and OSS Ventures, underscores the growing need for robust and integrated health management solutions in industries such as energy, manufacturing, and defense.
The traditional approach to employee health management in these sectors has been marred by the use of fragmented tools that are often poorly suited for multi-site and international operations. MyC is poised to change this landscape with its comprehensive platform that covers both occupational health and first-line medical care, ensuring a high level of security and compliance with international standards.
At the heart of MyC's platform is the automation of operational processes, including pharmaceutical management, medical records management with specialist consultations, and regulatory reporting. This not only enhances operational efficiency but also enables rapid, large-scale deployments, even in environments with limited connectivity. Founded by Dr. Laurent Bonnardot, an ENT physician and emergency doctor with extensive experience in isolated and complex environments, and Benjamin Crevant, an entrepreneur from the industrial sector, MyC is uniquely positioned to address the structural challenges faced by organizations in managing employee health.
The implications of MyC's platform extend beyond the operational efficiencies it offers. For everyday users, this could mean better access to medical care and follow-up, even in the most remote or challenging environments. From an industry perspective, MyC's solution has the potential to reshape how companies approach employee health, prioritizing both the well-being of their workforce and compliance with stringent regulatory requirements.
As MyC plans to strengthen its product roadmap and scale its sales and marketing teams, the company is set to support broader adoption among international enterprise clients. This expansion could lead to a paradigm shift in how employee health is managed globally, especially in sectors where the risk to workers is highest. With its robust SaaS technology and strong domain expertise, MyC is well-placed to deliver tangible operational value to essential industries, making it a significant player in the healthtech sector.
The funding round is a testament to the potential of MyC's platform to address a critical need in the market. As Valérie Gombart, co-founder and Managing Director of Hi Inov, noted, the investment aligns with the strategy to support European B2B companies that deliver operational value to essential industries. With this backing, MyC is poised to make a significant impact on the future of employee health management, setting a new standard for how companies care for their workers in the most challenging environments.
For businesses operating in high-risk sectors, MyC's platform offers a compelling solution to the perennial challenge of managing employee health. By providing a single, integrated platform that can cover all needs from on-site medical follow-up to multi-country regulatory compliance, MyC is set to become an indispensable tool. As the company looks to the future, its focus on delivering operational value and its commitment to supporting essential industries position it for growth and success in the healthtech market.
In conclusion, MyC's €10 million funding round is more than just an investment in a promising startup; it represents a significant step forward in the evolution of employee health management. With its innovative platform, MyC is not only transforming the way companies approach worker health but also contributing to a safer, more efficient, and more compliant work environment across high-risk industries. As the healthtech sector continues to evolve, MyC is certainly a company to watch, given its potential to make a lasting impact on the lives of workers worldwide.
The traditional approach to employee health management in these sectors has been marred by the use of fragmented tools that are often poorly suited for multi-site and international operations. MyC is poised to change this landscape with its comprehensive platform that covers both occupational health and first-line medical care, ensuring a high level of security and compliance with international standards.
At the heart of MyC's platform is the automation of operational processes, including pharmaceutical management, medical records management with specialist consultations, and regulatory reporting. This not only enhances operational efficiency but also enables rapid, large-scale deployments, even in environments with limited connectivity. Founded by Dr. Laurent Bonnardot, an ENT physician and emergency doctor with extensive experience in isolated and complex environments, and Benjamin Crevant, an entrepreneur from the industrial sector, MyC is uniquely positioned to address the structural challenges faced by organizations in managing employee health.
The implications of MyC's platform extend beyond the operational efficiencies it offers. For everyday users, this could mean better access to medical care and follow-up, even in the most remote or challenging environments. From an industry perspective, MyC's solution has the potential to reshape how companies approach employee health, prioritizing both the well-being of their workforce and compliance with stringent regulatory requirements.
As MyC plans to strengthen its product roadmap and scale its sales and marketing teams, the company is set to support broader adoption among international enterprise clients. This expansion could lead to a paradigm shift in how employee health is managed globally, especially in sectors where the risk to workers is highest. With its robust SaaS technology and strong domain expertise, MyC is well-placed to deliver tangible operational value to essential industries, making it a significant player in the healthtech sector.
The funding round is a testament to the potential of MyC's platform to address a critical need in the market. As Valérie Gombart, co-founder and Managing Director of Hi Inov, noted, the investment aligns with the strategy to support European B2B companies that deliver operational value to essential industries. With this backing, MyC is poised to make a significant impact on the future of employee health management, setting a new standard for how companies care for their workers in the most challenging environments.
For businesses operating in high-risk sectors, MyC's platform offers a compelling solution to the perennial challenge of managing employee health. By providing a single, integrated platform that can cover all needs from on-site medical follow-up to multi-country regulatory compliance, MyC is set to become an indispensable tool. As the company looks to the future, its focus on delivering operational value and its commitment to supporting essential industries position it for growth and success in the healthtech market.
In conclusion, MyC's €10 million funding round is more than just an investment in a promising startup; it represents a significant step forward in the evolution of employee health management. With its innovative platform, MyC is not only transforming the way companies approach worker health but also contributing to a safer, more efficient, and more compliant work environment across high-risk industries. As the healthtech sector continues to evolve, MyC is certainly a company to watch, given its potential to make a lasting impact on the lives of workers worldwide.